Studies

202605296

Adult Subjects Female Subjects Male Subjects

202603388

Heart Disease Diabetes Vascular Disease Healthy Subjects Adult Subjects Female Subjects Male Subjects

The goal of this clinical trial is to examine whether empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, improves vascular and autonomic function in adults with prehypertension. The main questions this clinical trial aims to answer are:

1. Does empagliflozin improve endothelial function?
2. Does empagliflozin improve sympathetic nervous system function?

This clinical trial employs a double-blind, placebo-controlled crossover study lasting up to 6 weeks for participants with prehypertension and up to 2 weeks for normotensive participants. Participants with prehypertension will take empagliflozin or placebo for 2 weeks, separated by a 2-week washout. Normotensive participants will complete baseline, pre-treatment visits only and will serve as a control group.